MXPA04009535A - Terapia con estatina para mejorar el mantenimiento cognoscitivo. - Google Patents
Terapia con estatina para mejorar el mantenimiento cognoscitivo.Info
- Publication number
- MXPA04009535A MXPA04009535A MXPA04009535A MXPA04009535A MXPA04009535A MX PA04009535 A MXPA04009535 A MX PA04009535A MX PA04009535 A MXPA04009535 A MX PA04009535A MX PA04009535 A MXPA04009535 A MX PA04009535A MX PA04009535 A MXPA04009535 A MX PA04009535A
- Authority
- MX
- Mexico
- Prior art keywords
- statin
- statin therapy
- enhancing cognitive
- galantamine
- active ingredient
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrane Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
Abstract
La presente invencion se refiere a un metodo para tratar demencia o un trastorno de memoria que comprende la administracion de una cantidad terapeuticamente efectiva de galantamina (I) y una estatina (II); la invencion se refiere ademas a productos que contienen como primer ingrediente activo galantamina (I) y como segundo ingrediente activo una estatina (II), como preparaciones combinadas para uso simultaneo, separado o consecutivo en el tratamiento de pacientes que sufren de Alzheimer o demencias relacionadas; a composiciones farmaceutica y usos relacionados.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36928502P | 2002-04-02 | 2002-04-02 | |
| PCT/EP2003/003324 WO2003082298A1 (en) | 2002-04-02 | 2003-03-28 | Statin therapy for enhancing cognitive maintenance |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA04009535A true MXPA04009535A (es) | 2005-01-25 |
Family
ID=28675573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04009535A MXPA04009535A (es) | 2002-04-02 | 2003-03-28 | Terapia con estatina para mejorar el mantenimiento cognoscitivo. |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1492539B1 (es) |
| JP (1) | JP2005525391A (es) |
| KR (1) | KR100986194B1 (es) |
| CN (1) | CN100528164C (es) |
| AT (1) | ATE331523T1 (es) |
| AU (1) | AU2003226753B2 (es) |
| BR (1) | BR0308293A (es) |
| CA (1) | CA2480275C (es) |
| CY (1) | CY1105545T1 (es) |
| DE (1) | DE60306503T2 (es) |
| DK (1) | DK1492539T3 (es) |
| EA (1) | EA013069B1 (es) |
| ES (1) | ES2268393T3 (es) |
| HK (1) | HK1079688A1 (es) |
| IL (2) | IL164317A0 (es) |
| MX (1) | MXPA04009535A (es) |
| NO (1) | NO20044698L (es) |
| NZ (1) | NZ536111A (es) |
| PL (1) | PL211160B1 (es) |
| PT (1) | PT1492539E (es) |
| UA (1) | UA79605C2 (es) |
| WO (1) | WO2003082298A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1603548A4 (en) * | 2003-02-05 | 2007-10-10 | Myriad Genetics Inc | COMPOSITION AND METHOD FOR TREATING NEURODEGENERATIVE DISORDERS |
| AU2005232447A1 (en) * | 2004-04-14 | 2005-10-27 | Warner-Lambert Company Llc | Therapeutic combination for treatment of Alzheimers disease |
| WO2005123068A2 (en) * | 2004-06-08 | 2005-12-29 | Axonyx, Inc. | Methods of dealying alzheimer’s disease progression using a beta-amyloid precursor protein inhibitor and a hmg coa reductase inhibitor |
| GB0607946D0 (en) * | 2006-04-21 | 2006-05-31 | Minster Res The Ltd | Mono and combination therapy |
| AU2007299726A1 (en) * | 2006-09-22 | 2008-03-27 | Braincells, Inc. | Combination comprising an HMG-COA reductase inhibitor and a second neurogenic agent for treating a nervous system disorder and increasing neurogenesis |
| TWI432195B (zh) | 2007-10-03 | 2014-04-01 | Kowa Co | 神經細胞死亡抑制劑 |
| US20160303146A1 (en) * | 2013-12-13 | 2016-10-20 | David A. TABACZYNSKI | Inhibition of isoprenoid biosynthetic pathways to treat neuroinflammatory disorders |
-
2003
- 2003-03-28 EA EA200401295A patent/EA013069B1/ru not_active IP Right Cessation
- 2003-03-28 PT PT03745196T patent/PT1492539E/pt unknown
- 2003-03-28 PL PL371551A patent/PL211160B1/pl unknown
- 2003-03-28 WO PCT/EP2003/003324 patent/WO2003082298A1/en active IP Right Grant
- 2003-03-28 JP JP2003579835A patent/JP2005525391A/ja active Pending
- 2003-03-28 IL IL16431703A patent/IL164317A0/xx unknown
- 2003-03-28 BR BR0308293-8A patent/BR0308293A/pt not_active IP Right Cessation
- 2003-03-28 KR KR1020047013127A patent/KR100986194B1/ko active IP Right Grant
- 2003-03-28 NZ NZ536111A patent/NZ536111A/xx not_active IP Right Cessation
- 2003-03-28 CA CA2480275A patent/CA2480275C/en not_active Expired - Fee Related
- 2003-03-28 EP EP03745196A patent/EP1492539B1/en not_active Expired - Lifetime
- 2003-03-28 UA UA20040806803A patent/UA79605C2/uk unknown
- 2003-03-28 ES ES03745196T patent/ES2268393T3/es not_active Expired - Lifetime
- 2003-03-28 DK DK03745196T patent/DK1492539T3/da active
- 2003-03-28 MX MXPA04009535A patent/MXPA04009535A/es active IP Right Grant
- 2003-03-28 CN CNB038073854A patent/CN100528164C/zh not_active Expired - Fee Related
- 2003-03-28 AT AT03745196T patent/ATE331523T1/de active
- 2003-03-28 AU AU2003226753A patent/AU2003226753B2/en not_active Ceased
- 2003-03-28 DE DE60306503T patent/DE60306503T2/de not_active Expired - Lifetime
-
2004
- 2004-09-28 IL IL164317A patent/IL164317A/en not_active IP Right Cessation
- 2004-10-29 NO NO20044698A patent/NO20044698L/no not_active Application Discontinuation
-
2005
- 2005-12-21 HK HK05111808.4A patent/HK1079688A1/xx not_active IP Right Cessation
-
2006
- 2006-09-27 CY CY20061101397T patent/CY1105545T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ536111A (en) | 2006-03-31 |
| CA2480275C (en) | 2011-08-16 |
| HK1079688A1 (en) | 2006-04-13 |
| CY1105545T1 (el) | 2010-07-28 |
| WO2003082298A1 (en) | 2003-10-09 |
| EP1492539B1 (en) | 2006-06-28 |
| JP2005525391A (ja) | 2005-08-25 |
| DE60306503T2 (de) | 2007-06-21 |
| AU2003226753B2 (en) | 2007-06-28 |
| PT1492539E (pt) | 2006-11-30 |
| PL371551A1 (en) | 2005-06-27 |
| KR100986194B1 (ko) | 2010-10-07 |
| CN100528164C (zh) | 2009-08-19 |
| IL164317A (en) | 2010-04-29 |
| EA013069B1 (ru) | 2010-02-26 |
| CN1642555A (zh) | 2005-07-20 |
| EA200401295A1 (ru) | 2005-02-24 |
| KR20040096608A (ko) | 2004-11-16 |
| AU2003226753A1 (en) | 2003-10-13 |
| CA2480275A1 (en) | 2003-10-09 |
| ES2268393T3 (es) | 2007-03-16 |
| DK1492539T3 (da) | 2006-10-30 |
| ATE331523T1 (de) | 2006-07-15 |
| DE60306503D1 (de) | 2006-08-10 |
| IL164317A0 (en) | 2005-12-18 |
| NO20044698L (no) | 2004-10-29 |
| BR0308293A (pt) | 2004-12-28 |
| EP1492539A1 (en) | 2005-01-05 |
| UA79605C2 (en) | 2007-07-10 |
| PL211160B1 (pl) | 2012-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60126980D1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
| MXPA05006940A (es) | Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide. | |
| MXPA02011303A (es) | Nueva composicion farmaceutica. | |
| ATE219363T1 (de) | Lösliche prodrugs von paclitaxel | |
| PL309604A1 (en) | Pharmaceutical composition for treating nicotin dependence | |
| HK1079688A1 (en) | Statin product for enhancing cognitive maintenance | |
| PL374443A1 (en) | Novel pyrimidineamide derivatives and the use thereof | |
| TW200633694A (en) | Composition and method for treating asthma | |
| ATE273693T1 (de) | Proteinhaltige arzneimittel | |
| UA32457C2 (uk) | Лікарський засіб (варіанти) і спосіб медикаментозного впливу на організм | |
| IL136733A0 (en) | Pharmaceutical composition containing sibutramine and orlistat | |
| BG104179A (en) | Phanquinon administration for the treatment of the alzheimer's disease | |
| BG105342A (en) | Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases | |
| GB2331926A (en) | Pharmaceutical compositions containing ibuprofen and domperidone for the treatment of migraine | |
| TW200700075A (en) | Roflumilast and integrin inhibitor combination and method of treatment | |
| ATE293445T1 (de) | Herstellung reiner stereoisomere von tricyclo- (5.2.1.0(2.6) )-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel | |
| GEP20053512B (en) | S-Methyl-Dihydro-Ziprasidone for Treatment of Psychiatric and Ocular Disorders. | |
| WO2004030684A3 (en) | Kavalactone product | |
| NZ268914A (en) | Use of efaroxan and derivatives to prepare medicaments for treating neurodegenerative diseases especially alzheimer's disease | |
| DE69434002D1 (de) | 2,3 diaryl-1-benzopyrame zur behandlung von dermatitis | |
| UA41326C2 (uk) | Фармацевтична композиція для профілактики або лікування вірусних захворювань, засіб для профілактики або лікування вірусних захворювань | |
| WO2003066806A3 (en) | Therapeutic use of aziridino compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |